ArQule, Inc. (ARQL) insider have most recently took part in a trading activity. On Aug 25, 2017 Pucci Paolo, Chief Executive Officer bought 9,492 shares having total worth of $9,967 at the price of $1.05 per share, following the transaction a total of 364,270 shares owned by Pucci Paolo.
Shares of ArQule, Inc. (ARQL) traded up 1.9% on Aug 25, 2017, hitting $1.07. 61,780 shares of the company’s stock traded hands. ArQule, Inc. has a 52 week low of $0.94 and a 52 week high of $1.92. The company’s market cap is $126 million.
ArQule, Inc. (ARQL) last announced its earnings results on Aug 4, 2017. The company reported -0.10 earnings per share (EPS) for the quarter, higher than the consensus estimate of -0.11 by $0.01. During the same quarter in the previous year, the company posted -0.07 earnings per share. The company’s revenue for the quarter was down 100% on a year-over-year basis.
|earnings per share||-0.10||-0.11||-0.10||-0.08||-0.07||-0.08||-0.05||-0.04||-0.06||-0.07|
ArQule, Inc. was incorporated in Delaware. The Company is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics. It employ technologies such as its ArQule Kinase Inhibitor Platform (‘AKIP’) to design and develop drugs that have the potential to fulfill this mission. Its product candidates and programs span a continuum of research and development ranging from drug discovery to advanced clinical testing. Its product candidate is tivantinib (ARQ 197), an orally administered, small molecule inhibitor of the c-Met receptor tyrosine kinase. C-Met is a promising target for cancer therapy, based on its multiple roles in cancerous cell proliferation, tumor spread, new blood vessel formation and resistance to certain drug therapies. The Company and its partners, Daiichi Sankyo Co., Ltd. (‘Daiichi Sankyo’) and Kyowa Hakko Kirin Co., Ltd. (‘Kyowa Hakko Kirin’), are implementing a clinical development program designed to realize the broad potential of tivantinib as a well-tolerated single agent and in combination with other anti-cancer therapies in a number of disease indications The Company has licensed commercial rights to tivantinib for human cancer indications to Daiichi Sankyo in the U.S., Europe, South America and the rest of the world, excluding Japan and certain other Asian countries, where it has licensed commercial rights to Kyowa Hakko Kirin. Its proprietary pipeline is directed toward molecular targets and biological processes with demonstrated roles in the development of human cancers. The advanced candidates in this pipeline are ARQ 087, an inhibitor of fibroblast growth factor receptor, ARQ 621, an inhibitor of the Eg5 kinesin motor protein, and ARQ 736, an inhibitor of the RAF kinases, all of which are in Phase 1 clinical testing. Its drug discovery efforts are engaged mainly on AKIP, which it is using to generate compounds designed to inhibit kinases without competing with adenosine triphosphate (‘ATP’) for binding to the target kinase, as well as other types of kinase inhibitors. ATP is a chemical found in all living cells and is the energy source involved in a variety of physiological processes. The Company faces competition from pharmaceutical companies, biotechnology companies and academic and research organizations. The Company’s product candidates, as well as the activities associated with their research, development and commercialization, are subject to extensive regulation by the FDA in the United States and by comparable authorities in other countries.
Latest posts by William White (see all)
- Insider Activity to Watch: Hooper Holmes, Inc. $HPHW - November 24, 2017
- Recent Insider Activity: EnSync, Inc. $ESNC - November 24, 2017
- Recent Insider Activity: IsoRay, Inc. $ISR - November 24, 2017